secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2021-07-16T23:59:59+00:00
Accession:  0001564590-21-036895
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Enanta CMO Nathalie Adda to retire Feb 28, 2022; consulting deal signed
-----------------------------------------------------------------------

- Nathalie Adda, MD, SVP and CMO, announced retirement effective February 28, 2022.
- Enanta entered a consulting agreement for up to 3 months post-retirement at $450/hour for up to 70 hours/month.
- Existing stock options and restricted stock units will continue to vest during the consulting term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000156459021036895/0001564590-21-036895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000156459021036895/enta-8k_20210714.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-036895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer